The administration of the non-psychotropic plant constituent cannabidiol (CBD) is associated with a significant reduction in psychotic symptoms in patients with schizophrenia, according to clinical trial data published in the journal Translational Psychiatry.
Cannabidiol Relieves Psychosis in Schizophrenia, Why Illegal?
